WilmerHale Advises Visterra in $46.7M Series C Financing

• 10.17.2017

On October 5, 2017, Visterra, Inc., a clinical-stage biotechnology company that uses its novel Hierotope® platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines against such targets that are not adequately addressed with conventional approaches, announced that it has completed a Series C financing round raising a total of $46.7 million, including a new extension totaling $23.6 million.

The WilmerHale team representing Visterra in this transaction included Lia Der Marderosian, Molly Fox, Emily Gainor and Sam Rothberg.

Visterra's press release is available at www.visterrainc.com.